Skinject Patch

About Skinject

Skinject is a private, pre-revenue biotech company advancing a dissolvable microneedle patch for the treatment of non-melanoma skin cancers. Its technology, co-invented at the University of Pittsburgh and Carnegie Mellon University, aims to deliver a chemotherapy agent intradermally to kill cancer cells and stimulate an immune response, potentially reducing recurrence. The company is in the pre-clinical/development stage, targeting a large and growing market dominated by surgical procedures, with a regimen designed for simple, weekly in-office application over three weeks.

About Skinject

Skinject is a private, pre-revenue biotech company advancing a dissolvable microneedle patch for the treatment of non-melanoma skin cancers. Its technology, co-invented at the University of Pittsburgh and Carnegie Mellon University, aims to deliver a chemotherapy agent intradermally to kill cancer cells and stimulate an immune response, potentially reducing recurrence. The company is in the pre-clinical/development stage, targeting a large and growing market dominated by surgical procedures, with a regimen designed for simple, weekly in-office application over three weeks.

About Skinject

Skinject is a private, pre-revenue biotech company advancing a dissolvable microneedle patch for the treatment of non-melanoma skin cancers. Its technology, co-invented at the University of Pittsburgh and Carnegie Mellon University, aims to deliver a chemotherapy agent intradermally to kill cancer cells and stimulate an immune response, potentially reducing recurrence. The company is in the pre-clinical/development stage, targeting a large and growing market dominated by surgical procedures, with a regimen designed for simple, weekly in-office application over three weeks.

Therapeutic Areas

Other Basal Cell Carcinoma (BCC) Drugs